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Nanoscaled polymer composites were prepared from polysaccharide chitosan (CS) and Ca-deficient hydroxyapatite
(CDHA). CS-CDHA nanocomposites were synthesized by in situ precipitation at pH 9, and the CS-CDHA carriers were
then fabricated by ionic cross-linking methods using tripolyphosphate and chemical cross-linking methods by
glutaraldehyde and genipin. Certain biomolecules such as vitamin B12, cytochrome c, and bovine serum albumin
were loaded into the CS-CDHA carriers, and their release behaviors were investigated. Furthermore, these CS-CDHA
carriers were examined by transmission electron microscopy, electron spectroscopy for chemical analysis, and X-ray
diffraction. The release behavior of the biomolecules was controlled by the CS/CDHA ratios and cross-linked agents.
By increasing the concentration of CS and the concentration of the cross-linking agents, cross-linking within carriers
increases, and the release rate of the biomolecules is decreased. Moreover, the release rate of the biomolecules
from the CS-CDHA carriers at pH 4 was higher than that at pH 10, displaying a pH-sensitive behavior. Therefore,
these CS-CDHA hydrogel beads may be useful for intelligent drug release and accelerate bone reconstruction.
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Recently, much attention has been focused on chitosan
(CS)-based hydrogel for cartilage tissue engineering and
bone substitute with controlled release function due to
its structure similar to that of natural glycosaminoglycan
[1-3]. CS is a cationic polysaccharide with an isoelectric
point of 6.2 [4], thus is pH sensitive and has been proposed
for electrically modulated drug delivery [5]. Furthermore,
CS has been identified as hydrophilic, non-toxic, biodegrad-
able, antibacterial, and biocompatible. In our previous study
[6], we demonstrated that the addition of clay to the CS
matrix could strongly affect the cross-linking density as well
as the mechanical properties, swelling-deswelling behavior,
and fatigue property of the nanohybrids. Hence, the in-
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in any medium, provided the original work is pmontmorillonite is expected to electrostatically interact
with the positively charged -NH3
+ group of CS to generate
a strong cross-linking structure in the nanohydrogel
[7], thus strongly affect the macroscopic property of
the nanohydrogel and the drug diffusion through the
bulk entity.
There have been some reports in the preparation of
CS nanoparticles by ionic and chemical cross-linking
methods, for example, the use of an ionic gelation method
to prepare CS NPs as reported by Calvo et al. [8]. Cationic
CS nanoparticles were formed through the inter- and
intra-cross-linking of the amino groups of CS with the
negatively charged phosphate groups of tripolyposphate
(TPP). TPP is a non-toxic polyanion which can interact
with CS via electrostatic forces to induce ionic cross-linked
networks [9], which could be used for the preparation of
CS hydrogel beads owing to its immediate gelling ability.
Furthermore, Mi et al. [10] reported the preparation of
chitosan gel using a natural chemical cross-linker, i.e.,
genipin (GP), which is obtained from its parent compound
traditionally used as a component of Chinese medicine,n open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.















Figure 1 XRD patterns of pristine CS, pristine CDHA, and
various CS-CDHA nanocomposites. Red circle: peak of CS;






Figure 2 TEM images of CS-CDHA nanocomposites. (a) Pristine CDHA,
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Ellis. GP cross-linked networks in the biopolymers display
significantly less cytotoxicity than those chemical cross-
linked by glutaraldehyde (GA) and thus recently was widely
used for various biomedical applications [11-14].
The purpose in this study is to modulate the release
rate of biomolecules from highly swollen hydrogel beads
and its loose structure [15] in order to extend the drug
release period of the CS hydrogel. The drug release perme-
ability of CS can be further regulated by the incorporation
of Ca-deficient hydroxyapatite (Ca10−x(PO4)6−x (HPO4)x
(OH)2−x, 0 ≤ x ≤ 1, CDHA, Ca/P = 1.5) nanorods, because
it has long been employed to improve the mechanical
strength and osteoconductivity of chitosan [16-18]. The
influence of the nanofiller (CDHA nanorods) in the CS
hydrogel for the drug release behavior might be critical
and can be explored further.
Therefore, the major research objective of this study is
to explore the role of CDHA nanorods in the release
behavior of biomolecules (vitamin B12, cytochrome c, and





(b) CS37, (c) CS55, and (d) CS73 nanocomposites.





























































Figure 3 ESCA spectra of CS-CDHA nanocomposites. (a) N1s, (b)
Ca2p, and (c) P2p for pristine CS, pristine CDHA, and CS37 nanocomposites.
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of cross-linking in the CS hydrogel beads were also
investigated. This study is expected to provide a fundamental
understanding of the CS-CDHA nanocomposite drugcarrier used for medical applications and also of the
drug (growth factor) delivery to enhance bone repair.
Methods
Synthesis of CS-CDHA nanocomposites
CS-CDHA nanocomposites with various CDHA con-
tents were prepared via in situ processes to characterize
the influence of nanofiller and polymer-filler interaction
on the behavior of this drug delivery system. Chitosan
(molecular weight 215 kDa, 80% degree of deacetylation)
was purchased from Sigma-Aldrich (St. Louis, MI, USA).
CS solution (1% (w/v)) was first prepared by dissolving
the CS powder in 10% (v/v) acetic acid solution. For the
in situ process (PO4
3−→CS→Ca2+), H3PO4 aqueous solu-
tion (0.167 M) was first added into the CS solution, and Ca
(CH3COO)2 aqueous solution (0.25 M) was then added
into this mixture solution under stirring for 12 h. The pH
value was kept at 9 by adding NaOH solution (1 M). The
nanocomposites with different volume ratios of CS/CDHA
were modulated at 0/100, 10/90, 30/70, 50/50, 70/30, and
100/0, abbreviated as CDHA, CS19, CS37, CS55, CS73,
and CS, respectively. Subsequently, these CS-CDHA
nanocomposites were dried at 65°C for 24 h.
Preparation of CS-CDHA hydrogel beads
Various ratios of CS/CDHA nanocomposites and biomole-
cules (vitamin B12, 1,355 Da; cytochrome c, 12,327 Da; or
BSA, 65,000 Da) were dissolved in the 10% (v/v) acetic acid
solution and then the mixing solution was dropped into the
different concentrations of TPP (1, 5, 10 wt.%) for ionic
cross-linking or further chemical cross-linking by GA or
GP under stirring. The morphology of the CS-CDHA
carriers (diameter 500 to 1,000 μm) was evaluated using
an optical microscope (OM).
Characterization
The crystallographic phase of the CDHA/CS nanocomposites
was identified by X-ray diffraction (XRD, M18XHF, Mac
Science, Tokyo, Japan). The morphology of the CDHA
nanocrystals and various CS-CDHA nanocomposites
were observed by transmission electron microscopy
(TEM, JEOL-2000FX, Tokyo, Japan). The chemical struc-
ture change was evaluated by electron spectroscopy for
chemical analysis (ESCA), equipped with MgKα at 1,253.6
eV and 150 W power at the anode. A survey scan of the
varying electron volts for N1s, Ca2p, and P2p was taken.
Drug release test
These nanocomposite hydrogel beads were put into
phosphate-buffered solution (pH 7.4) to test for drug
release. The release medium was withdrawn for each
juncture and replaced with equivalent volume of fresh
buffer. UV-visible spectroscopy (Agilent 8453, Agilent




























Figure 4 OM photos and vitamin B12 cumulative release (%) of various CS/CDHA nanocomposites hydrogel beads. TPP 10%, scale bar = 200 μm.
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amount of vitamin B12 (361 nm), cytochrome c (410 nm),
or BSA (562 nm, using BCA kits) released via the
use of predetermined standard concentration-intensity
calibration curve.
The drug release percent was determined using
Equation (1) [19]:
Cumulative release %ð Þ ¼ Rt=L 100%; ð1Þ
where L and Rt represent the initial amount of drug
loaded and the cumulative amount of drug released at
time t, respectively.
Results and discussion
The CS-CDHA nanohybrids were prepared using ionic
gelation. At first, H3PO4 solution was adsorbed on the CS
matrix and then Ca(CH3COO)2 solution (PO4
3−→CS→Ca2+)
was added. In this in situ precipitated method, CDHA
nanorods were encapsulated within polysaccharide CSFigure 5 OM photos and vitamin B12 cumulative release (%) of CS55
TPP 5%, and TPP 10%. Scale bar = 200 μm.matrix, resulting in a nanocomposite with homogeneous
nanostructure. At pH 9, the nanohybrids (CS and CDHA
nanocrystals) were observed. The CDHA nanorods were
incorporated into the CS polymer network homogeneously,
as shown in the XRD (Figure 1) pattern, TEM (Figure 2),
and ESCA (Figure 3).
Figure 1 shows the XRD patterns of the CDHA, CS, and
CS-CDHA nanocomposites. One major peak at 26° and
32°, and four minor peaks at 40°, 46°, 50°, and 53° were
observed (peak of pure CS appeared at 21°). According
to the ICDD No. 39–1894 and No. 46–0905, these
peaks could be identified as semi-crystalline of CS
(2θ approximately 21°) and crystalline of CDHA, respect-
ively. Using CS73 nanocomposite as an example, both CS
and CDHA characteristic peaks (seven peaks) were ob-
served. This indicated that the CDHA/CS nanocomposites
could be synthesized via in situ precipitated processes.
Furthermore, it was observed that the crystallinity of CS
decreased with increasing CDHA content, because the




















































Figure 6 OM photos and vitamin B12 cumulative release (%) in pH 4, pH 7.4, and pH 10. CS55 hydrogel beads, TPP 5%; scale bar = 200 μm.
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http://www.nanoscalereslett.com/content/8/1/417defects in the CS network. Moreover, it is also demon-
strated that strong polymer-filler interaction could modify
the molecular configuration of the polymer chains in
the vicinity of the filler to the formation of localized
amorphous regions. This would inhibit and retard the
crystalline development of the CS chains. It became more
pronounced when the CDHA content exceeds 30 wt.%.
However, the crystallinity of CDHA seems to be enhanced
by the addition of CS. The full-width at half maximum of
the XRD peak of the CS-CDHA nanocomposites was
observed to be lower than that of the pristine CDHA,
thereby displaying sharper peak (better crystallinity).
Thus, we suggest that the CS chains might induce the
crystallinity of CDHA.
Figure 2 shows the TEM images of the pristine CDHA
(a), CS37 (b), CS55 (c), and CS73 (d) nanocomposites. The
pristine CDHA exhibited needle-like structure of nanorods
(5 to 20 nm in diameter and 50 to 100 nm in length). The
CS-CDHA nanocomposites exhibited homogenously




















Figure 7 OM photos and vitamin B12 cumulative release (%) of chemical
by GA and GP after TPP 5% ionically cross-linked by TPP. Scale bar = 200 μm.CS73, as illustrated in Figure 2b,c,d. The reason is that
the electrostatic attraction between the NH3
+ group
(positive charge of the CS chains) and the PO4
3− group
(negative charge of the CDHA nanorods) served as the
stable force for the colloid suspension, favoring the disper-
sion of CDHA. Moreover, the structure of the CS-CDHA
nanocomposites (CS73) became denser with the increase of
the CS content due to the better compatibility and stable
network of high molecular weight of CS. In contrast, CS55
and CS37 exhibited less dense morphologies.
A comparison of the chemical binding energy change of
the pristine CDHA, pristine CS, and CS37 nanocomposites
was shown in the ESCA spectra. The ESCA analysis shows
that the surface was mainly composed of N, Ca, and P
atoms, which could represent the chemical structure and
interaction of CS (N atom) and CDHA (Ca and P atoms).
Figure 3a shows the ESCA data of N1s scan spectra in
CS, CDHA, and CS37. The N1s peak in the pristine CS
was found at 402.3 eV, implying the amino group of CS





































Figure 8 OM photos and cumulative release (%) of vitamin B12, cytochrome c, and BSA in CS55 hydrogel beads. TPP 10%, scale bar = 200 μm.
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implying the complex formation of CS and CDHA. Two
Ca2p peaks of the pristine CDHA were observed with the
binding energy of 347.8 eV (2p3/2) and 351.4 (2p1/2), as in-
dicated in Figure 3b. Two peaks (2p3/2 348.0 eV and 2p3/2
351.6 eV) were exhibited in CS37 and displayed 0.2 eV
chemical shift compared to the pristine CDHA, suggesting
the formation of CDHA in the CS37 and some chemical
interaction between CS and CDHA (no additional peak
in the pristine CS). Similar with the ESCA spectrum of
Ca2p, 0.8 eV (133.1-eV shift to 133.9 eV) chemical shifts
were found between the pristine CDHA and CS37 in
the P2p spectrum. These results indicate that the CDHA
nanorods were grown in the CS matrix through in situ
precipitated process.
When it was fully ionic cross-linked by P3O10
3− ions in
the TPP solution, CS with positive charge (NH3
+) would
consume most of the binding sites and interact with the
negatively charged phosphate groups of TPP. The model
biomolecules were encapsulated into the CS-CDHA
carriers (hydrogel beads) to evaluate their suitability as
a delivery system. Figure 4 show the OM images of theCh
CDBiomolecules/Drug
(Cross-linked by TPP, GA and GP
Figure 9 Novel chitosan/Ca-deficient hydroxyapatite nanocompositeCS-CDHA carriers of the pristine CS and various ratios
of CS-CDHA nanocomposites cross-linked by 10% TPP
(diameter 500 to 1,000 μm). With the increase of CS,
the hydrogel beads exhibited more stable and denser
chemical structure, showing higher cross-linked density by
TPP and thicker wall of beads (dark and black corona). It
exhibits very loose structure in CS19, but dense morph-
ology in CS91. The cumulative release rate (vitamin B12)
of these CS-CDHA nanocomposites is in the order of
CS19 > CS37 > CS55 > pristine CS > CS91 > CS73. CS73
showed the lowest drug cumulative release because it has
the highest compact structure, as shown in the TEM image
(Figure 2). We suggest that CDHA might play an important
role, limiting the path of drug release in a suitable addition
ratio of CDHA.
Figure 5 shows the effect of the ionic cross-linker
(TPP) concentration for drug (biomolecules) release. The
result indicates that higher concentration of TPP would
cause the lowering of drug release due to the stronger
network of the hydrogel beads. Stable hydrogel beads were
difficult to form with 1% TPP due to weak cross-linkage.
Furthermore, pH-sensitive behavior was found in theitosan
HA
)
Nanocomposites made by 
in-situ process
(P Chitosan Ca (pH9)
via an in situ precipitation process at pH 9.
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nature. The CS polymer chains would swell and expand
at pH below 6.2 (isoelectric point of chitosan is 6.2) but
deswell and shrink at pH above 6.2. Thus, rapid release
of CS55 hydrogel beads was observed at pH 4, while slow
release occurred at pH 10 (Figure 6). The OM image of
hydrogel beads at pH 10 displayed thicker corona wall;
thus, drug release is slowest at pH 10.
In order to achieve sustained release behaviors, the
chemical cross-linkers (GA and GP) were used to increase
the density and strength of cross-linking in the CS-CDHA
carriers. Figure 7 demonstrated that GA-cross-linked
hydrogel beads display the slowest release rate. The result
suggests the capability of cross-linking using GA is better
than those using GP and TPP. However, GA is toxic to
human bodies, which would generate some side effects. In
contrast, GP is a nature cross-linker (non-cytotoxic), which
is a good candidate for modified CS-CDHA carriers. The
reacting time of GP is very slow; therefore, the CS-CDHA
carriers need to be cross-linked by TPP first to solidify
the structure before reacting with GP. This is the optimum
process to achieve the sustained release purpose.
Finally, the comparison of the different molecular weight
effects of biomolecules was investigated. Figure 8 shows that
the slower drug release occurred in larger biomolecules,
displaying in the order of BSA (65, 000 Da) < cytochrome
c (12,327 Da) < vitamin B12 (1,355 Da). The result illus-
trated that the rate of drug release would be changed with
different sizes of biomolecules due to the pore-size barrier
of the CS-CDHA carriers. Therefore, a suitable drug carrier
would be anticipated to fabricate for various sizes of bio-
molecules (such as growth factors and therapeutic drugs)
to achieve the sustained release for biomedical applications.
Conclusion
Novel biocompatible hybrid nanocomposites consisting of
chitosan and CDHA were successfully synthesized via an
in situ precipitation process at pH 9 (Figure 9) for drug
delivery purpose. CS/CDHA nanocomposites were then
cross-linked into hydrogel beads by tripolyphosphate,
glutaraldehyde, and genipin, respectively. Various biomole-
cules could be encapsulated in the beads and exhibit differ-
ent release behaviors. Experimental results show that the
drug release kinetics of the CS-CDHA carriers was affected
by the incorporation of CDHA nanoparticles. The slowest
release rate was observed in CS73 (30% CDHA addition)
due to its more stable structure and smaller pore size.
Therefore, CDHA nanocrystal can simultaneously function
as a bioactive filler and drug release regulator. The drug
release rate of biomolecules also could be modulated by
cross-linked agent. The application of GA will produce
the densest structures, leading to the slowest drug release
of biomolecules. These CS-CDHA carriers also exhibited
pH-sensitive behavior. It displayed faster release rate atpH value of 4 and slowest release rate at pH value of 10,
due to swelling behavior of CS at pH 4. It might provide
valuable information for a better design of chitosan hybrids
for drug-loaded implant with improved bioactivity and con-
trolled drug release function. Furthermore, chitosan-CDHA
nanocomposite drug carriers with pH-sensitive property
which can lead to intelligent controlled release of drugs
can be used as gastric fluid-resistant drug vehicles and
for bone repair.
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